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_________________________________________________________________________25 
ABSTRACT 26 
 27 
The roles of an exopolysaccharide (EPS) extract from Lactobacillus fermentum Lf2 were 28 
studied individually or combined with a probiotic strain, Bifidobacterium 29 
animalis subsp. lactis INL1. EPS in its purified form caused an increase in the levels of 30 
cytokine TNF-α; both purified and crude EPS produced an increase in the regulatory 31 
cytokine IL-10. BALB/c mice received yoghurt with no additives (Y), with EPS (YE), with 32 
bifidobacteria (YB), or both (YEB) for 25 days. Only the YE group presented significantly 33 
increased concentrations of total short chain fatty acids (p < 0.05) including acetic and 34 
butyric acids; the levels of the C. coccoides cluster also rose over time (p < 0.05) for this 35 
group. A possible bifidogenic role was observed with the YEB group, reflected in the 36 
increasing levels of the genus Bifidobacterium along time (p < 0.05); this was not observed 37 
when the probiotic was administered solely (YB group).  38 
_________________________________________________________________________ 39 
 40 
  41 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
1. Introduction 42 
 43 
Whereas probiotics are live microorganisms that when administered in adequate 44 
amounts confer a health benefit on the host (Hill et al., 2014), prebiotics are non-viable 45 
substrates that function as nutrients for beneficial microorganisms harboured by the host, 46 
including administered probiotic strains and indigenous microorganisms. Thus, a prebiotic 47 
should elicit a metabolism biased towards health-promoting microorganisms within the 48 
indigenous ecosystem. According to the consensus statement by ISSAP, the definition of a 49 
prebiotic has been recently modified to ‘a substrate that is selectively utilized by host 50 
microorganisms providing a health benefit’ (Gibson et al., 2017), including the impact of 51 
prebiotic at extraintestinal sites: on bone strength, neural and cognitive processes, immune 52 
functioning, skin, and serum lipid profile (Collins & Reid, 2016; Gibson et al., 2017). In 53 
addition, the term synbiotics refers to a combination of both, probiotics and prebiotics in a 54 
synergic way, so this term should be reserved for products in which the prebiotic 55 
compound(s) selectively favours the probiotic organism(s) (Cencic & Chingwaru, 2010). 56 
The catabolism of prebiotic carbohydrates by the metabolic activity of the gut 57 
microbiota primarily produces three short chain fatty acids (SCFAs): acetate, propionate 58 
and butyrate. The most abundant SCFA in the colon is acetate and, in general, represents 59 
more than half of SCFA content detected in faeces (Louis, Scott, Duncan, & Flint, 2007). 60 
The prebiotic substrates are able to selectively promote the growth of beneficial 61 
microorganisms and induce changes in the levels of these acids in healthy individuals 62 
(Lecerf et al., 2012). Thus, the levels of these SCFAs represent an indirect measure of the 63 
level of beneficial microorganisms and their impact on human health. 64 
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Some lactic acid bacteria (LAB) are able to produce exopolysaccharide (EPS) as 65 
part of their metabolism; these polymers can be released to the medium exerting 66 
technological and functional roles. Regarding their functional properties, EPS from LAB 67 
have demonstrated several benefits including bifidogenic/prebiotic effects, 68 
immunomodulatory properties, prevention of pathogenic bacteria, gastritis, antitumor and 69 
antioxidant activities, among others (Ale et al., 2016a; Hamet, Medrano, Pérez, & 70 
Abraham, 2016; Polak-Berecka, Waśko, Szwajgier, & Chomaz, 2013; Rodríguez, Medici, 71 
Rodríguez, Mozzi, & Font de Valdez, 2009; Wang et al., 2014).  72 
In this regard, Sarikaya, Aslim, and Yuksekdag (2017) reported that the lyophilised 73 
EPS from Lactobacillus fermentum LB-69 presented both bifidogenic and anti-biofilm 74 
effects (in vitro) against a strain of Bacillus cereus. Furthermore, Lactobacillus rhamnosus 75 
E/N is a probiotic strain that synthesises EPS with significant bifidogenic and antioxidant 76 
activities (Polak-Berecka et al., 2013). These positive aspects make EPS, as well as the 77 
producer strains, suitable ingredients for the formulation of novel functional foods.  78 
In general, EPS are produced in situ during fermentation process of dairy food 79 
when, for example, EPS+ starter or adjunct cultures are added to the food matrices to 80 
improve the textural and organoleptic characteristics of the final product (Amatayakul, 81 
Sherkat, & Shah, 2006; Hassan, Ipsen, Janzen, & Qvist, 2003). Only a few studies have 82 
described the effects of the direct application of bacterial EPS extracts as food additives. 83 
For example, a crude EPS from Streptococcus thermophilus suspended in milk was 84 
proposed to effectively prevent or heal chronic gastritis in a murine model (Rodríguez et 85 
al., 2009; Rodríguez, Medici, Mozzi, & de Valdez, 2010). So far, no report describes the 86 
application of EPS extracts as food ingredients in yoghurt, this option being an interesting 87 
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proposal in the case the EPS-producing strains are not suitable for growing in a food 88 
matrix. 89 
L. fermentum Lf2 is an autochthonous strain that was isolated as non-starter culture 90 
from a local semi-hard cheese with blowing defects. This strain produces high amounts of 91 
EPS when it grows under controlled conditions of temperature (30 ºC) and pH (6.0), 92 
reaching 0.8 g L-1, approximately, in semi-defined medium (SDM; Kimmel & Roberts, 93 
1998) broth (Ale et al., 2016b). The total EPS is composed mainly of two polysaccharides: 94 
a β-glucan whose repeating unit is a trisaccharide (1.8 × 103 KDa), and a 95 
heteropolysaccharide constituting a disaccharide repeating unit of glucose and galactose, 96 
the main backbone being composed of α-(1→6) linked galactose residues, each one 97 
substituted by a terminal glucose residue (90 KDa) (unpublished data). From previous 98 
studies, this EPS extract presented not only interesting technological characteristics, such as 99 
an increase in consistency and pseudoplasticity of yoghurts (Ale et al., 2016b), but also 100 
positive health effects, protecting against a Salmonella infection and increasing the levels 101 
of IgA in intestinal fluid of mice (Ale et al., 2016a).  102 
On the other hand, Bifidobacterium animalis subsp. lactis INL1 was isolated from 103 
breast milk and, as L. fermentum Lf2, belongs to the Instituto de Lactología Industrial 104 
(INLAIN) collection. This bifidobacterium has been widely studied regarding its 105 
technological and probiotic properties: resistance to storage in acidified milk, stability to 106 
spray-drying and freezing processes and IgA- mediated immunomodulation (Zacarías, 107 
Binetti, Laco, Reinheimer, & Vinderola, 2011), protection against acute and chronic colitis 108 
in spray dried form (Burns et al., 2017), and protection against Salmonella infection 109 
(Zacarías, Reinheimer, Forzani, Grangette, & Vinderola, 2014). 110 
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In the present work, the EPS extract from L. fermentum Lf2 was evaluated in vitro 111 
to preliminarily analyse its immunomodulatory role. In addition, the EPS was added to 112 
yoghurt, alone or combined with the probiotic strain B. animalis subsp. lactis INL1, to 113 
evaluate (in vivo assay) the effects on the gut microbiota (potential prebiotic effect) of the 114 
EPS or a synergic interaction (potential synbiotic effect) when they are administrated 115 
together. For this purpose, different bacterial groups were determined in faeces, as well as 116 
the levels of SCFA at different periods post treatment. IgA and cytokines levels were also 117 
measured in intestinal fluid and small intestine, respectively, and histological analyses were 118 
done at the end of the assay to evaluate if epithelial damage occurred in large and small 119 
intestines. The aim of this work was to develop a functional yoghurt with synbiotic 120 
properties. 121 
 122 
2. Materials and methods 123 
 124 
2.1.  Organisms and growth conditions  125 
 126 
L. fermentum Lf2 and B. animalis subsp. lactis INL1 (INLAIN collection) were 127 
stored at –80 °C in MRS (De Man, Rogosa and Sharpe, Biokar, Beauvais, France) broth 128 
plus 15% (v/v) glycerol. They were routinely grown in MRS broth at 37 °C for 16 h in 129 
aerobiosis and anaerobiosis (Anaeropack Anaero, Mitsubishi Gas Chemical Co., Inc., 130 
Germany) plus 0.1% (w/v) cysteine, respectively.  131 
For yoghurt production, two commercial strains, Streptococcus thermophilus SC42 132 
and L. delbrueckii subsp. bulgaricus 254 (both from Biochemical, Argentina), were 133 
selected based on their inability (visual test) to produce EPS in milk. They were routinely 134 
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grown in 10% (w/v) reconstituted skimmed milk (RSM) at 43 °C and stored at -80 °C in the 135 
same medium. 136 
To design the calibration curves for qPCR analysis (Supplementary material, Table 137 
S1,), the following strains were used as well: Bifidobacterium breve 110 (INLAIN 138 
collection) and Bifidobacterium bifidum ATCC 35914 were cultured in the same way as B. 139 
animalis subsp. lactis INL1. S. thermophilus SC42 was grown in Elliker broth (Biokar) at 140 
42 °C; Escherichia coli EC101 in LB (Luria-Bertani) broth, with continuous agitation, at 37 141 
°C under aerobiosis and Staphylococcus aureus 76 (INLAIN collection) was developed in 142 
tryptic soy (TS) broth (Biokar) at 37 °C in aerobiosis. All cultures were grown from an 143 
isolated colony. 144 
 145 
2.2.  EPS production of L. fermentum Lf2 146 
 147 
EPS production was carried out as described by Ale et al. (2016b). Briefly, 148 
cultivations were performed in a 2-L fermenter (Sartorius Biostat A plus®, Goettingen, 149 
Germany) in SDM (Kimmel & Roberts, 1998) broth with the aim to minimise interferences 150 
in EPS isolation by replacing yeast extract, beef extract and proteose peptone from MRS 151 
broth by yeast nitrogen base and Bacto Casitone (both from Difco, Becton, Dickinson and 152 
Company, Le Pont de Claix, France). L. fermentum Lf2 was inoculated from an overnight 153 
culture (0.1%, v/v) and incubations were made at 30 °C for 72 h, with agitation (6 rpm) and 154 
sparging with CO2 (0.2 L min-1). The pH was kept automatically at 6.0 with sterile 8 M 155 
NaOH. After incubation, bacteria were removed by centrifugation (19,630 × g, 30 min, 5 156 
°C) and EPS was extracted and precipitated at 4 °C for 48 h by adding 2 volumes of chilled 157 
absolute ethanol (Cicarelli, Buenos Aires, Argentina). The precipitate was collected by 158 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
centrifugation (4,050 × g, 30 min, 5 °C), dissolved in ultrapure water and dialysed against 159 
distilled water, using 12–14 kDa MWCO membranes (Sigma Aldrich, St. Louis, MO, 160 
USA) for 3 days, at 4 °C with daily change of water. Finally, the EPS solution was freeze-161 
dried (Chris Alpha 1-4 LD Plus, Tokyo, Japan), weighed and expressed as mg crude EPS L-162 
1
. Additionally, a purification of the EPS crude fraction was performed with a treatment 163 
with DNAse I (5 µg mL-1; Sigma Aldrich) at 37 °C for 12 h and Pronase E (50 µg mL-1; 164 
Roche, Germany) at 37 °C for 18 h. Then, a precipitation step with TCA (12%, w/v) with 165 
subsequent neutralisation with NaOH was done. The suspension was dialysed against 166 
distilled water and freeze-dried as indicated above to obtain the EP  purified fraction 167 
(López et al., 2012). 168 
 169 
2.3.  Preliminary in vitro assay to analyse the immunomodulatory role of EPS 170 
 171 
The THP-1 cell line was routinely grown in RPMI medium (Roswell Park Memorial 172 
Institute medium, RPMI-1640 medium, Sigma Aldrich) containing 10% (w/v) of foetal 173 
bovine serum and 50 mg mL-1 of streptomycin and penicillin. The cell line was incubated at 174 
37 °C with 5% CO2. The THP-1 monocytes were differentiated into macrophages by 175 
incubation with phorbol 12-myristate 13-acetate 50 mM (PMA, Sigma Aldrich) for 48 h, 176 
followed by an incubation for 24 h in RPMI medium. Macrophages derived from THP-1 177 
were stimulated with crude or purified EPS: 60 µg mL-1 of the crude form containing 0.9% 178 
proteins according to the Bradford method (Bio-Rad), and 12.6 µg mL-1 of the purified 179 
form. This last concentration was proposed taking into account that, after purification of the 180 
crude EPS extract, 21% (approximately) of purified EPS is recovered. This way both 181 
samples contain approximately the same proportion of EPS. A positive control treated with 182 
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lipopolysaccharide (LPS, 0.5 µg mL-1) was also included. The cells were incubated at 37 183 
°C, with 5% CO2 for 4 h for the detection of TNF-α, and 8 h for IL-6 and IL-10 184 
determinations. The cytokine analysis was performed from the culture supernatants using 185 
the DuoSet ELISA kits (R&D Systems, Minneapolis, United States) according to the 186 
protocols recommended by the supplier. A negative control with untreated cells was also 187 
included. All determinations were made in quadruplicate. 188 
 189 
2.4.  In vivo assay to analyse the functional role of EPS as food ingredient in yoghurt 190 
 191 
2.4.1.  Manufacture of yoghurts  192 
Yoghurts were made with 10% (w/v) RSM inoculated with S. thermophilus SC42 193 
and L. delbrueckii subsp. bulgaricus 254 (106 and 105 cfu mL-1, respectively), with 0 194 
(control) and 600 (equivalent to 146 mg pure EPS L-1) mg L-1 of crude EPS added. The 195 
incubation was at 43 °C until a final pH value of 4.6 was reached. The concentration of 196 
crude EPS was chosen according to a previous study in which the crude extract at 600 mg 197 
L-1 exerted protection against Salmonella infection (Ale et al., 2016a). After fermentation, 198 
yoghurts were immediately cooled and stored at 4 °C. The following day an overnight 199 
culture of B. animalis subsp. lactis INL1 was washed twice with sterile PBS and 200 
resuspended in yoghurt with 0 or 600 mg L-1 of EPS extract at a level of 5 × 108 cfu mL-1; 201 
this way the final cell count was not reduced during yoghurt manufacture. 202 
 203 
2.4.2.  Animals and feeding procedures 204 
For in vivo trials, 6-week old male BALB/c mice weighing 19–21 g were obtained 205 
from the random-bred colony of the Centro de Experimentaciones Biológicas y Bioterio 206 
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(FCV-UNL, Esperanza, Santa Fe, Argentina). Animals were humanly handled according to 207 
the National Institutes of Health guide for the care and use of Laboratory animals (NIH 208 
8023, 1978). In addition, all the procedures were approved by the Ethical Committee for 209 
Animal Experimentation (FCV-UNL, Esperanza, Santa Fe, Argentina), and were made 210 
following the recommendations of the INLAIN animal facility (Zacarías et al., 2014). 211 
Twenty eight mice were clustered in four groups (seven mice/group) and received, 212 
during 25 consecutive days and by gavage, 300 µL d-1 of any of the following samples: Y, 213 
yoghurt; YE, yoghurt + 600 mg EPS L-1 (equivalent to 9 mg kg-1 d-1); YB, yoghurt + 5×108 214 
cfu mL-1 B. animalis subsp. lactis INL1; YEB, yoghurt + 600 mg EPS L-1 + 5×108 cfu mL-1 215 
B. animalis subsp. lactis INL1. All animals simultaneously and ad libitum received sterile 216 
tap water and a conventional balanced diet (Cooperación, Buenos Aires, Argentina). The 217 
diet composition was the following: 230 g kg-1 protein, 60 g kg-1 crude fibre, 100 g kg-1 218 
total minerals, 13 g kg-1 Ca, 8 g kg-1 de P, 120 g kg-1 water and vitamins. 219 
 220 
2.4.3.  Bifidobacteria counts in faeces 221 
Faeces samples were obtained at 0, 8, 18 and 25 days by the use of individual 222 
metabolic cages (Tecniplast, Buguggiate, Italy) for cell counts of total bifidobacteria, DNA 223 
extraction and SCFA quantification. Total bifidobacteria were determined on RCM agar 224 
(Reinforced Clostridial Medium, Biokar) with the selective supplement for bifidobacteria 225 
MUP (mupirocin, Merck, Darmstadt, Germany) according to Fanning et al. (2012), at 226 
initial time (before receiving treatment) and at 8, 18 and 25 days post-treatment. The 227 
selection of this medium was based on the supplementation with MUP, an antimicrobial 228 
compound that acts as a selective agent for the inhibition of anaerobic bacteria with the 229 
exception of bifidobacteria. The first dilution was done in sterile PBS buffer and the 230 
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mixture was placed in stomacher for 3 min at maximum speed. Successive dilutions were 231 
done in 0.1% peptone water (w/v). The plates were incubated under anaerobiosis 232 
(Anaerocult®, Merck) at 37 °C for 48 h and the morphology of the different colonies was 233 
verified microscopically (1000×, phase contrast), selecting those typical of bifidobacteria. 234 
 235 
2.4.4.  Estimation of the levels of different bacterial groups in faeces by qPCR 236 
Total DNA was extracted using the QIAmp DNA Stool Mini kit (Qiagen) from the 237 
diluted faeces (1:10 in PBS) that were previously homogenised by stomacher (3 min at 238 
maximum speed). Samples were kept at –20 °C until the moment of DNA extraction and 239 
subsequent amplification. The selection of the microbial groups that were analysed was 240 
based on in vivo studies carried out by reference groups using BALB/c mice (Gómez-241 
Gallego et al., 2012).  242 
The quantitative PCR was done with a StepOnePlus thermocycler (Applied 243 
Biosystems, Foster City, CA, USA), using the Power SYBR Green PCR Master Mix 244 
(Applied Biosystems). The reaction cycles, for all cases, were: 95 °C during 10 min and 40 245 
cycles of amplification (95 °C for 15 s, T° annealing for 1 min). The optimal annealing 246 
temperatures for each reaction, the primers used, the efficiencies obtained in each 247 
calibration curve, as well as and the standard used, are detailed in Supplementary material 248 
Table S1. The R2 values were higher than 0.994 in all cases.  249 
DNA extractions from cultures were performed with the same kit used for mouse 250 
faeces but from 5 mL of an overnight culture, to which a cell count was done on the same 251 
day of the extraction. Three of the standard DNAs were purchased from the German culture 252 
collection (DSMZ): DSM 17677 from Clostridium leptum, DSM 20438 from 253 
Bifidobacterium catenulatum, DSM 935 from Clostridium coccoides, and for practical 254 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
purposes DNA was considered to come from an initial culture of 1×108 cfu mL-1. All 255 
cultures were grown from an isolated colony and all determinations were made, at least, in 256 
duplicate for each sample. For primers corresponding to species B. breve and B. bifidum, as 257 
well as for the genus Staphylococcus, values lower than the detection limit were obtained in 258 
all samples analysed. 259 
 260 
2.4.5.  Quantification of SCFAs in faeces 261 
The determination of SCFAs was carried out from faeces using HPLC at initial 262 
time, 8, 18 and 25 days post-treatment, according to Ferrario et al. (2014) with some 263 
modifications. The samples were diluted 1:10 in sterile PBS, treated in stomacher (3 min at 264 
maximum speed) and centrifuged 10 min at 10,000 × g. Then the supernatant was acidified 265 
with a fixed volume of concentrated H2SO4 for all samples until pH 2 was reached, 266 
centrifuged as described previously, and finally filtered (45 µm, Millipore) before injecting 267 
the samples to the equipment. The chromatographic system consisted of a quaternary pump, 268 
an in-line degasser, a manual injector, an oven for temperature control of the column and 269 
two in-line detectors: UV-visible (210 nm) and refractive index (Perkin Elmer). The data 270 
were analysed and processed using the Chromera® software. An Aminex HPX-87H, 300 × 271 
7.8 mm column, an Aminex Cation-H column guard (30 × 4.6 mm) (Bio-Rad Laboratories) 272 
and an isocratic flow of 0.6 mL min-1 with a mobile phase of H2SO4 0.01 M were used, at a 273 
temperature of 65 °C. The identification was made with the UV and IR detectors comparing 274 
the retention times of standard solutions (Sigma Aldrich), while the quantification was 275 
carried out by means of the refractive index detector, since the chromatograms obtained 276 
were cleaner. Three replicates of each sample were done. 277 
 278 
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2.4.6.  Determination of s-IgA and cytokines in small intestine  279 
After the feeding period, animals were injected intraperitoneally with an anaesthetic 280 
cocktail prepared with 1.8 mL of ketamine (50 mg mL-1, KetonalTM, Richmond Vet 281 
Pharna, Argentina), 0.9 mL of xylazine 2% (Alfasan, Argentina), 0.3 mL of acepromazine 282 
(10 mg mL-1, Acedan, Hollyday, Argentina) to a final volume of 10 mL, adding 7 mL of 283 
sterile saline solution. It was kept at 4 °C until the moment of application (0.3 mL per 284 
mouse). Mice were then sacrificed by cervical dislocation. Liver was removed and 285 
homogenised in 5 mL sterile PBS and pour plated onto ABRV agar (37 °C for 24 h in 286 
aerobiosis) to evaluate translocation of enterobacteria to liver. s-IgA and cytokines were 287 
determined as described previously by Ale et al. (2016a). s-IgA was determined in 288 
intestinal fluid and cytokines IL-10, IL-6, TNF-α and IFN-γ were determined in the distal 289 
small intestine tissue (jejunum and ileum), using the corresponding mouse ELISA Set (BD 290 
OptEIA, BD, Biosciences PharMingen, San Diego, CA, USA).  291 
 292 
2.4.7.  Histological analysis 293 
Histological analysis was done as described by Burns et al. (2017). Briefly, it 294 
consisted of placing the tissues in cassettes for histology and submerging them overnight in 295 
a solution of formaldehyde (4%, v/v, in PBS; Ciccarelli, Buenos Aires, Argentina). The 296 
next day, the tissues were dehydrated by successive passages in solutions with increasing 297 
concentrations of ethyl alcohol. For rinsing, the cassettes were allowed to dry on absorbent 298 
paper and treated with toluene for 30 min. Once dried, the samples were embedded in 299 
paraffin and the sections were kept at 4 °C. For the histological analysis, 5 µm sections 300 
were made and stained with May Gründwald (MG)-Giemsa. The dye MG was diluted 1: 5 301 
and the Giemsa 1: 100 in distilled water. The paraffin was removed and the sections were 302 
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rehydrated in successive baths of toluene, ethyl alcohol and, finally, distilled water. The 303 
coloration consisted in leaving the section 15 min in MG (37 °C), 40 min in Giemsa (37 304 
°C) and two subsequent baths in distilled water. For the differentiation, the samples were 305 
placed 30 s in acetic acid (dilution 1: 100) and 10 s in alcohol/acetone (50: 50). Finally, the 306 
assembly was carried out, leaving the sections in toluene for a few seconds. A drop of 307 
EUKITT® (Sigma Aldrich) was placed on each slide and they were allowed to dry at room 308 
temperature. At least two sections were analysed per animal. 309 
 310 
2.5.  Statistical analysis 311 
 312 
For statistical analysis, SPSS software (SPSS Inc., Chicago, IL, USA) was used. 313 
ANOVA or Kruskal-Wallis was applied if the ANOVA assumptions were not satisfied, to 314 
analyse the treatment factor at a fixed time. The differences between means were 315 
determined by the Tukey test or by Dunns, respectively. Repeated measures test was 316 
applied to analyse the factor time. Sphericity criteria was always verified by the Mauchly 317 
test, and the multivariate statistics were considered in the case this criterium was not 318 
satisfied. Multiple comparisons were made with Bonferroni. The differences were 319 
considered significant when p < 0.05 for all the tests described above. In addition, a 320 
principal components analysis was included for SCFAs and bacterial groups, for which the 321 
Minitab 16 statistical program (Minitab Inc., State College, PA, USA) was applied. 322 
 323 
3. Results 324 
 325 
3.1.  Preliminary in vitro assay to analyse the immunomodulatory role of EPS 326 
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 327 
Table 1 shows the results obtained for the quantification of TNF-α, IL-6 and IL-10 328 
cytokines in the supernatant of the THP-1cells treated with purified and crude EPS, at a 329 
concentration of 12.6 µg mL-1 and 60 µg mL-1, respectively. Simultaneous comparisons 330 
were done between all groups: cells treated with crude or purified EPS, LPS or untreated 331 
cells. Regarding TNF-α cytokine, significant differences (p < 0.05) were observed between 332 
cells treated with LPS (lipopolysaccharide, positive control) and those untreated, as 333 
expected, and between purified EPS and control without treatment. No significant 334 
differences were detected for cell treated with crude EPS extract. On the other hand, EPS in 335 
either form, purified or crude, seem not to have affected the levels of cytokine IL-6. For the 336 
cytokine IL-10, there were no significant differences between the cells treated with pure 337 
and crude EPS, while the levels of cells treated with LPS or untreated could not be 338 
detected. 339 
 340 
3.2.  In vivo assay to analyse the functional role of EPS as a food ingredient in yoghurt 341 
 342 
The chosen dose for EPS extract was appropriate to address the experimental in 343 
vivo design, since no translocation was observed in mice from different groups, supporting 344 
the safety of the EPS and the probiotic strain (or their combination) at the proposed dose for 345 
oral consumption. 346 
 347 
3.2.1.  Bifidobacteria counts in faeces 348 
Fig. 1 shows the results for bifidobacteria counts at 8, 18 and 25 days of treatment, 349 
subtracting the initial level of bifidobacteria from each mouse, in logarithmic scale. After 8 350 
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days of treatment, significant differences were found between YE and YB groups, the latter 351 
presenting approximately one more order than the first. At 18 days no significant 352 
differences were seen between groups, probably due to the high variability obtained, and, at 353 
the end of the treatment. No group differed from the control group.   354 
The reason for the great variability observed (mainly at 18 days of treatment) 355 
remains unknown, but it could be due to intrinsic variability among mice population, as 356 
well as to the methodology employed for bacterial count. Although cell morphology was 357 
checked for all colonies, possibly some of them were not effectively bifidobacteria. DNA 358 
sequencing of each colony would have been needed to confirm its nature, but it was beyond 359 
the scope of this work. 360 
  361 
3.2.2.  Estimation of the levels of different bacterial groups in faeces by qPCR 362 
The universal primers were designed to have specificity with the conserved regions 363 
of the rRNA-16S of prokaryotic cells (Baker, Smith, & Cowan, 2003), so they are related to 364 
the total microbial load present in the intestine. In this case, no differences were observed 365 
between groups at each time evaluated, but a significant effect was observed for the control 366 
group (Y) during the time of treatment (Fig. 2A). At 25 days the levels of total bacteria 367 
were significantly lower (p < 0.05) than those observed at 8 and 18 days. For the remaining 368 
groups there were no significant differences throughout time.  369 
When the levels of the genus Bifidobacterium were estimated, significant 370 
differences were detected for the factors time and treatment (Fig. 2B). Differences among 371 
treatments were observed only at 25 days for the group YEB, which presented values 372 
significantly higher than the group YE (p < 0.05), but none differed from the control group 373 
(Y) and group YB. This was also confirmed by the cell count estimations, since at 25 days, 374 
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the group YEB presented higher levels of this genus in comparison with the group YE (Fig. 375 
1). When evaluating the influence of time on each treatment, the control group (Y) and the 376 
group that received only EPS (YE) presented levels significantly lower at 18 days than 377 
those obtained at 25 days, indicating that the population of bifidobacteria increased towards 378 
the end of the assay. No significant differences were observed during time for YB 379 
treatment, while the levels obtained after 25 days were higher than those observed at 8 and 380 
18 days for YEB group (p < 0.05). Thus, considering both factors, the results suggest that 381 
the combination of the two ingredients, EPS and the bifidobacteria, would play a possible 382 
synergic role, since the levels of the genus Bifidobacterium at the end of the treatment 383 
remained higher than those obtained at 8 and 18 days. It should be highlighted that, for the 384 
statistical analysis of the design applied, when the presence of repeated measures over time 385 
is considered as another source of variability, a better estimation of the error is produced. 386 
Estimations of the levels of the species B. catenulatum (Fig. 2C) in the mouse 387 
faeces were also done. As the interaction between time and treatment factors was 388 
significant, it was not possible to analyse them separately. When this occurred, ANOVA (or 389 
Kruskal-Wallis) was applied at fixed time points, since the treatment groups were 390 
independent. At 8 and 25 days no significant differences were observed between 391 
treatments, but at 18 days significant differences were observed among the groups Y and 392 
YE, presenting the latter minor levels. Apparently, neither the EPS extract nor the 393 
bifidobacteria would stimulate the development of this bacterial species in the intestinal 394 
tract of the animals. 395 
The levels of the B. animalis species were also determined by qPCR and the 396 
interaction between factors was again significant (p < 0.05). Differences were observed at 397 
all times evaluated and a general tendency to increase levels towards the end of the assay 398 
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was appreciated (Fig. 2D). After 8 days, the groups that received the bifidobacteria (YB 399 
and YEB) presented significantly higher levels than the control group (Y). Although this 400 
increment could be associated to the administration of the probiotic strain, it is interesting 401 
to evaluate the estimations after 18 days. In this case, the only group that presented 402 
significant differences in comparison with the control group was YEB, indicating that the 403 
combination of EPS and bifidobacteria was more effective in increasing the levels of the 404 
species B. animalis at this time. At 25 days, only significant differences were observed (p < 405 
0.05) between groups YEB and YE, but none was different from the control group. 406 
Regarding the C. coccoides group, time and treatment factors presented significant 407 
differences (Fig. 2E). YE group showed significantly lower levels than YEB group at 8 408 
days, but both were similar to the control group. When analysing the effect of time for each 409 
treatment, differences were detected (p < 0.05) between days 18 and 25 in comparison with 410 
day 8 for group YE, indicating a significant increase of this bacterial group which remained 411 
high towards the end of the treatment. For the group YEB, differences were seen between 412 
days 18 and 8, while time did not have a significant effect on the other treatments. This 413 
information suggests that EPS could be responsible for the increase in the levels of this 414 
bacterial group over time, being more effective after 18 days of administration, and this 415 
effect seems to be more important when EPS was combined with the probiotic strain at 18 416 
days of treatment. 417 
For the genera Streptococcus (Fig. 2F) and Lactobacillus (Fig. 2G) and the group of 418 
C. leptum (data not shown), no significant differences were observed among treatments and 419 
control group. 420 
 421 
3.2.3.  Quantification of SCFAs in faeces 422 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
Fig. 3A shows the results obtained for lactic acid; although it is not considered a 423 
SCFA, its levels are related to the metabolism of LAB and other intestinal bacteria. Also, it 424 
is feasible to be converted to butyrate and propionate by the gut microbiota (Bourriaud et 425 
al., 2005). In our study, after 8 days, group YB showed significantly higher concentrations 426 
of lactic acid than YE, but none was different from the control group. At 18 days no 427 
differences were observed between treatments, while at 25 days the control group Y 428 
presented higher lactic acid levels (p < 0.05) than the groups that received the 429 
bifidobacteria, either alone or together with the EPS. These results suggest that, despite the 430 
fact that the group YB reached high levels of lactic acid at 8 days, these levels were 431 
significantly lower at the end of treatment in comparison with the control group, either in 432 
combination or not with the EPS of L. fermentum Lf2.  433 
Regarding acetic acid (Fig. 3B), the group YE presented levels significantly higher 434 
at the end of the treatment in comparison with 8 days. For the other treatments, no 435 
significant changes were observed during the 25 days of intervention, or among the four 436 
groups at each time analysed. The same observations can be made for the results obtained 437 
for butyric acid and the sum of the three SCFAs (Fig. 3C and 3D, respectively), showing an 438 
increment in the levels of both acids for group YE. For propionic acid, despite presenting a 439 
similar behavior, no significant differences were observed among groups or during 440 
treatment (data not shown).  441 
These results indicate that the treatment that favours the production of acetic acid, 442 
butyric acid and the sum of the three SCFAs is YE. In the case of the combination of both 443 
ingredients (group YEB), no significant differences were observed during treatment. 444 
Considering these results, it seems that EPS alone is able to exert a clear effect on the 445 
production of SCFA, effect that was not detected when combined with the bifidobacteria. 446 
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The analysis of principal components (Fig. 4) was included to summarise the results 447 
for the levels of some bacterial groups studied (eight were included in this analysis, those 448 
which presented more influence) and the levels of the four organic acids at 25 days of 449 
treatment. From Figs. 4A and 4B, which show the score and loading graphs for the first two 450 
principal components (PC), respectively, it can be observed that all the variables of the 451 
bacterial groups impact mainly on the PC1, while, on the other hand, an influence mainly of 452 
organic acids is observed on the PC2. It could be appreciated that samples YEB and YB 453 
were grouped in the negative hemiplane of PC1, characterised by the variables 454 
Bifidobacterium, Streptococcus, B. animalis, B. catenulatum and C. coccoides.  455 
In general, samples YEB were grouped at a greater distance than YB from the 456 
origin, indicating that these variables have a greater effect on the YEB samples. The control 457 
samples (Y) were mainly grouped in the positive hemiplane of PC2, characterised by the 458 
variables lactic acid, enterobacteria and Lactobacillus. On the other hand, YE samples were 459 
grouped, together with YE and YB, in the negative hemiplane of PC2, characterised by 460 
butyric, acetic and propionic acids. It can be observed that the treatment with EPS (YE) 461 
caused a greater impact on the concentration of the SCFA in the faeces of the treated 462 
animals, while the treatment with the combination of both ingredients (YEB) had a more 463 
marked influence on the population of bifidobacteria mainly, and on the genus 464 
Streptococcus and the cluster C. coccoides, at 25 days. The group YB presented, on the 465 
other hand, an intermediate behaviour, located in the centre of the plane. 466 
  467 
3.2.4.  Determination of s-IgA and cytokines in small intestine 468 
Quantification of the level of different cytokines (IL-10, IL-6, IFN-γ and TNF-α) in 469 
small intestine tissue is shown in Fig. 5A. Although the two groups that received EPS 470 
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extract (YE and YEB) presented higher values of the regulatory cytokine IL-10 than the 471 
other groups, no significant differences were observed for all the cytokines evaluated. Fig. 472 
5B shows s-IgA concentrations in intestinal fluid and no significant differences were 473 
observed between treatments, probably because the maximum peak occurred before 25 474 
days. This could be justified considering that a significant increase in s-IgA concentration 475 
was observed at 15 days of treatment, when the EPS was added to yoghurt at half the 476 
concentration used in the present assay (Ale et al., 2016a). 477 
 478 
3.2.5.  Histological analysis 479 
The applied treatments caused no damage to the intestinal mucosa since normal 480 
morphology for both the small (Fig. 6) and large intestines (data not shown) of all the mice 481 
was observed. None of the tissues exhibited signs of inflammation or lymphocytic 482 
infiltration towards the mucosa and submucosa. 483 
 484 
4. Discussion 485 
 486 
By in vitro analysis, we could demonstrate that EPS from L. fermentum Lf2, in its 487 
purified form, caused an increase in the levels of the proinflammatory cytokine TNF-α, 488 
while both forms of EPS (purified and crude) produced an increase in the regulatory 489 
cytokine IL-10. As TNF-α is an important proinflammatory cytokine, a stimulation of its 490 
levels represents a typical immune tolerant phenotype. Both TNF-α and IL-6 play an 491 
important role in the signalling system for the initiation of the mucosal inflammatory 492 
response when the host intestinal epithelial surface is invaded by microbial pathogens (Jung 493 
et al., 1995). In addition, IL-10 is essential for maintaining the integrity and homeostasis of 494 
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the epithelial layers, limiting the damage caused by viral and bacterial infections through 495 
the repression of proinflammatory responses that could led to unnecessary tissue 496 
disruptions (Iyer & Cheng, 2012). Thus, TNF-α and IL-10 have potential implications 497 
given its central role in the inflammatory bowel diseases, both Crohn’s disease and 498 
ulcerative colitis (Papadakis & Targan, 2000).  499 
Gao et al. (2017) have reported changes in a number of proinflammatory cytokines 500 
(IL-12, IL-6 and TNF-α) with pre-treatment with EPS from L. rhamnosus GG in 501 
combination with LPS stimulation when compared with the LPS stimulation alone. López 502 
et al. (2012) studied the cytokines produced in peripheral blood mononuclear cells treated 503 
with EPS purified from different bifidobacteria. They did not detect any significant 504 
differences in the levels of IL-1β, IL-17 and IL-8 either with the presence of purified EPS 505 
or the EPS producing strains with respect to the control. In this case, the concentration of 506 
IL-10 was not modified with the EPS but it was increased with the producing bacteria, 507 
while the concentrations of IFN-γ and TNF-α were increased with both EPS and their 508 
producing bacteria In general, they observed that neutral and high molecular mass (> 103 509 
kDa; Vaningelgem et al., 2004) EPS were not efficient to induce the immune response, 510 
while those with low molecular mass (<103 kDa) and negative charge triggered a stronger 511 
response.  512 
Considering the chemical and structural characteristics of the L. fermentum Lf2 EPS 513 
extract (two uncharged fractions of low and high average molecular mass, unpublished 514 
data), it seems that the low molecular mass polysaccharide could have directed the response 515 
obtained, since it is present in a higher proportion than the high molecular mass 516 
polysaccharide (unpublished data). According to our results, the purified EPS from L. 517 
fermentum Lf2, at a single concentration studied (12.6 µg mL-1) was able to cause a 518 
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stronger immune response than the crude extract, stimulating the production of the 519 
cytokines TNF-α and IL- 10, while crude EPS (60 µg mL-1), induced only the production of 520 
IL-10. In view of this information, the purified form triggers a stronger immune response 521 
towards a proinflammatory profile when the concentrations between the cytokines TNF-α 522 
and IL-10 are compared (433 versus 28 pg mL-1). In contrast, crude EPS only significantly 523 
stimulates the production of IL-10 (37 pg mL-1) indicating that, possibly, there may be 524 
some components of unknown nature (maybe peptides or proteins) in the crude extract that 525 
inhibit the production of this proinflammatory cytokine. As described by Peña and 526 
Versalovic (2003), intestinal lactobacilli can produce soluble protein factors that 527 
presumably bind to cell surface receptors and inhibit synthesis or secretion of TNF‐α. 528 
These authors observed that, in the case of L. rhamnosus GG, a decrease of TNF‐α 529 
production in LPS‐activated murine macrophages took place by a contact‐independent 530 
manner. Further investigations should be carried out to elucidate the nature of the 531 
components present in the EPS crude extract and to probe the mechanisms of these effects 532 
and their in vivo relevance. 533 
Moreover, it is well known that gut microbiota dysbiosis impact in the development 534 
of diverse chronic disorders such as inflammatory bowel disease and, therefore, is a key 535 
target for the intervention with functional ingredients (probiotics and/or prebiotics), which 536 
could modify the altered gut microbiota, restoring the health state (Burns et al., 2017). In 537 
this scenario, EPS with functional properties demonstrated and administered as food 538 
ingredients (as in this case), could function as active players. For this reason, we decided to 539 
study the modifications of the mice microbiota caused by the administration of the EPS of 540 
L. fermentum Lf2 in a dairy matrix, alone or combined with a probiotic bifidobacterium. 541 
Although the faecal microbiota does not strictly reflect the entire gastrointestinal 542 
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ecosystem, the determination of bacterial levels in faeces can be considered an acceptable 543 
approximation of the bacterial content of the distal colon (Hamet et al., 2016). From the 544 
analysis of the universal primers, it could be suggested that the administration of EPS and 545 
B. animalis subsp. lactis INL1, separately or together, would prevent the decrease of the 546 
microbial load over time, when compared with the group that received only yoghurt.  547 
When the levels of the genus Bifidobacterium were estimated by cell counts, 548 
although it is more difficult to observe a clear tendency due to the variability of the results 549 
among animals, at day 25 the difference detected seems to obey exclusively to the presence 550 
of the bifidobacterium strain added. In this case, it would be more appropriate to considerer 551 
the results of qPCR determination for this bacterial genus due to the high specificity of the 552 
method. The qPCR results indicated that the combination of EPS and the probiotic strain 553 
(group YEB) seems to be effective in increasing the levels of the total Bifidobacterium 554 
during all the evaluated period (difference of 0.7 log cfu g-1), approximately, between 8 and 555 
25 days of treatment) when compared with the group of animals that received exclusively 556 
B. animalis INL1 (group YB; difference of 0.4 log cfu g-1), indicating that the combination 557 
of both ingredients exerted a possible bifidogenic role. Salazar, Gueimonde, Hernández-558 
Barranco, Ruas-Madiedo, and de Los Reyes-Gavilán (2008) observed, by batch cultures of 559 
faecal samples, that 11 different bifidobacterial EPS had a bifidogenic effect, detecting 560 
(PCR-DGGE) changes of other microbial groups during fermentation, mainly of 561 
Bacteroides, E. coli and microorganisms related to the second. Hamet et al. (2016) showed 562 
by DGGE that, when kefiran was orally administered to BALB/c mice, it modified the 563 
intestinal and faecal microbiota, increasing the population of bifidobacteria. Sarikaya et al. 564 
(2017) found that the lyophilised EPS of L. fermentum LB-69, at a concentration of 1 mg 565 
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mL-1, exerted a bifidogenic effect on B. breve BASO-1 strain and prevented the formation 566 
of biofilms by pathogenic bacteria.  567 
In our case, although at 25 days of treatment the group YEB showed significant 568 
differences only with group YE, we consider that, since the repeated measures test presents 569 
a better estimation of the error than ANOVA, it would be also valid to evaluate the 570 
evolution along time for each group. For the bifidobacteria species analysed, B. 571 
catenulatum and B. animalis, no significant changes during time of treatment could be 572 
evaluated due to the significant interaction among factors. But, when comparison among 573 
treatments was considered, for the first one a lower level (p < 0.05) was observed at 18 574 
days for mice that received EPS (YE) with respect to the control group, but this difference 575 
was not appreciated at the end of treatment. In the case of B. animalis, the groups that 576 
received the bifidobacteria with EPS (YEB) or alone (YB), presented significantly higher 577 
levels than the control group at 8 days of treatment, which remained significant only for the 578 
group YEB at 18 days. At the end of treatment, all groups were statistically similar to the 579 
control group. These results suggest that the administration of EPS could have helped to 580 
maintain the levels of this species different from the control group for a longer time of 581 
treatment. 582 
SCFAs are volatile fatty acids produced by the gut microbiota in the large bowel as 583 
fermentation products from food components that are unabsorbed/undigested in the small 584 
intestine, having distinct physiological effects. It has been shown that bifidobacteria can 585 
protect the host against enteropathogenic infections through the production of acetate 586 
(Fukuda et al., 2011). Acetate has been related to appetite reduction through its interaction 587 
with the central nervous system (Frost et al., 2014) and the three SCFAs have been 588 
associated with intestinal anti-inflammatory properties (Tedelind, Westberg, Kjerrulf, & 589 
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Vidal, 2007). Butyrate participates in the motility of the colon, reduces inflammation, 590 
increases visceral irrigation, induces apoptosis and inhibits the progression of tumour cells, 591 
properties that contribute with the prevention of colorectal cancer (Canani, 2011; Zhang et 592 
al., 2010).  593 
From qPCR quantifications, the levels of C. coccoides (group that belong to the 594 
Clostridium cluster XIVa), were favoured over time for EPS consumption, either 595 
individually or in combination with the bifidobacterium. This group has been described as 596 
an essential component of the human gut microbiota (Duncan, Barcenilla, Stewart, Pryde, 597 
& Flint, 2002), being responsible for the synthesis of large amounts of butyrate that is not 598 
only used as the main energy source of the colon epithelial cells (Barcenilla et al., 2000; 599 
Duncan et al., 2002), but also inhibits the expression of proinflammatory cytokine mRNA 600 
in the mucosa (Segain et al., 2000). In addition, the decrease in this group has been related 601 
to a higher incidence of Crohn's disease (Manichanh et al., 2006). Considering this 602 
information, the increase in the final concentration of butyric acid in faeces for the group 603 
YE could be probably associated to the increase observed for the Clostridium coccoides 604 
cluster. These results suggest a positive impact on health, evidencing a functional role of 605 
the EPS produced by L. fermentum Lf2. In a review by Besten et al. (2013), the relationship 606 
between SCFA and intestinal microbiota was described. According to this work, the 607 
phylum Bacteroidetes would be related to the production of acetate and propionate, while 608 
the phylum Firmicutes (including Clostridium genera) would be more linked to the 609 
synthesis of butyrate, reinforcing the observations of our study. The results regarding the 610 
qPCR determinations, as well as the SCFA levels, were summarised in the biplot (PCA 611 
analysis), which indicated that an increase in the levels of Bifidobacterium, Streptococcus, 612 
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B. animalis, B. catenulatum and C. coccoides can be related to the YEB group, while 613 
increased levels of SCFA can be related to the group that received EPS solely (YE). 614 
When the role of EPS on immunomodulation was analysed by determining the 615 
levels of s-IgA and cytokines in small intestine, no effect was evidenced at 25 days of 616 
treatment. Although in a previous report an immunomodulatory effect (increase on the level 617 
of s-IgA) was observed for this EPS extract after 15 days of administration (Ale et al., 618 
2016a), a consequence of the prolonged administration could be assumed in the present 619 
study. The observations by other authors (Moreno de LeBlanc et al., 2008) could justify our 620 
results. 621 
 622 
5. Conclusion 623 
 624 
We demonstrated that, when added as a food ingredient in yoghurts, the EPS crude 625 
extract from L. fermentum Lf2 exerted a possible prebiotic role reflected in an increase in 626 
SCFA levels in faeces towards the end of the treatment, which could be explained by an 627 
increase in the levels of the bacterial groups that are known to produce these beneficial 628 
acids for health (cluster XIVa of Clostridium, also known as C. coccoides group). When 629 
this EPS was combined with the probiotic strain B. animalis subsp. lactis INL1, a 630 
bifidogenic effect throughout the time of treatment was appreciated, improving the effect 631 
observed for both individual ingredients, fact that could be associated with a possible 632 
synergism between them, suggesting a possible synbiotic role. Although it would be 633 
necessary to demonstrate the effective health benefit associated to the recent definition of 634 
prebiotic, considering our results, together with previous studies referring to other 635 
functional (protection against Salmonella infection and immunomodulation) and 636 
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technological properties, the application of the EPS crude extract from L. fermentum Lf2 as 637 
a potential techno-functional ingredient can be proposed for the design of novel foods. 638 
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Figure legends 1 
 2 
Fig. 1. Bifidobacteria counts in faeces. Cell counts at initial time (t0) were subtracted from 3 
those obtained at 8, 18 and 25 days for each mouse, in logarithmic scale. ̅ ± SEM (vertical 4 
bars) is presented for each group at different times: , YE (group treated with crude EPS); 5 
, YB (group treated with B. animalis subsp. lactis INL1); , YEB (group treated with 6 
both ingredients); , Y (control group). Different letters indicate significant differences 7 
among groups at a fixed time point; determinations were done at least in duplicate. 8 
 9 
Fig. 2. Levels of different bacterial groups in faeces by qPCR: A, universal primers; B, 10 
Bifidobacterium; C, B. catenulatum; D, B. animalis; E,  Clostridium coccoides; F, 11 
Streptococcus; G, Lactobacillus. ̅ ± SEM (vertical bars) is presented for each group at 12 
different times: , YE (group treated with crude EPS); , YB (group treated with B. 13 
animalis subsp. lactis INL1); , YEB (group treated with both ingredients); , Y (control 14 
group). Different letters indicate significant differences among groups at a fixed time point, 15 
while different number of asterisks indicates significant differences throughout time of 16 
treatment for each group separately; determinations were done in triplicate. Levels at t0 17 
were subtracted for each mouse, in logarithmic scale.  18 
 19 
Fig. 3. Concentrations of different organic acids in faeces by HPLC: A, lactic acid; B, 20 
acetic acid; C, butyric acid; D, total SCFAs. ̅ ± SEM (vertical bars) is presented for each 21 
group at different times: , YE (group treated with crude EPS); , YB (group treated with 22 
B. animalis subsp. lactis INL1); , YEB (group treated with both ingredients); , Y 23 
(control group). Different letters indicate significant differences among groups at a fixed 24 
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time point, while different number of asterisks indicates significant differences throughout 25 
time of treatment for each group separately. Concentrations at t0 were subtracted for each 26 
mouse. Determinations were done in triplicate. 27 
 28 
Fig. 4. Principal components analysis for different bacterial groups and organic acids 29 
determined at 25 days of treatment. A) score and B) loading graphs are presented: , YE 30 
(group treated with crude EPS); , YB (group treated with B. animalis subsp. lactis INL1); 31 
, YEB (group treated with both ingredients); , Y (control group).  32 
 33 
Fig. 5. Boxplots for cytokines analysis in small intestine (A; asterisks indicate outliers), and 34 
bar plot for s-IgA levels in intestinal fluid (B; 	± SEM is represented): Y, control group; 35 
YB, group treated with B. animalis subsp. lactisINL1; YE, group treated with crude EPS; 36 
YEB, group treated with both ingredients. Assays were done in triplicate. 37 
 38 
Fig. 6. Histological analysis of the distal small intestine (jejunum and ileum) by May 39 
Grünwald Giemsa staining (10×). A, control group (Y); B, group treated with crude EPS 40 
(YE); C, group treated with both ingredients (YEB); D, group treated with B. animalis 41 
subsp. lactis INL1 (YB). 42 
 43 
 44 
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Table 1 
Preliminary in vitro assay with crude (60 µg mL-1) or purified (12.6 µg mL-1) EPS extract 
with THP-1 cell line. a 
 
 
 
a
 Different superscript letters indicate significant differences between groups for each 
cytokine analysed (p < 0.05). LPS, positive control; N.D., not detected. 
 
 
 
 
 
Cytokines Sample  ± SD (pg mL-1) 
TNF-α Crude extract 3 ± 3b 
Purified extract 433 ± 161a 
Negative control 0.5 ± 0.1b 
LPS 289 ± 45a 
IL-6 Crude extract 11 ± 2b 
Purified extract 10 ± 1b 
Negative control 8 ± 2b 
LPS 23 ± 2a 
IL-10 Crude extract 37 ± 30a 
Purified extract 28 ± 10a 
Negative control N.D. 
LPS .D. 
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